Boston, MA – June 16, 2025 — Pinco Biotherapeutics, a preclinical company developing a DNA plasmid–based therapy for neuropathic pain, announced its participation in the BIO International Convention 2025. The company attended with an Exhibitor-Only Pass provided by the Maryland Department of Commerce, highlighting Maryland’s continued support for emerging biotechnology companies.

The BIO International Convention is the largest global gathering of biotechnology companies, investors, pharmaceutical partners, and industry leaders. Pinco used the opportunity to engage in strategic partnering discussions, meet potential collaborators, and further position its non-viral gene therapy platform within the broader pain and neurology landscape.

“Our participation at BIO reinforced the strong industry interest in novel pain therapeutics,” said Scott Alpizar, PhD, CEO of Pinco Biotherapeutics. “We were able to engage with potential strategic partners, investors, and service providers as we advance toward in-vivo validation of our Nav1.7-targeting plasmid.”

Pinco’s plasmid is strategically designed to provide durable, tunable, and non-addictive relief for chronic neuropathic pain by selectively silencing the Nav1.7 sodium channel in relevant neurons. The company is currently advancing in-vitro optimization and preparing for expanded preclinical studies.

About Pinco Biotherapeutics

Pinco Biotherapeutics is a preclinical therapeutics company developing non-viral DNA plasmid–based drugs for chronic neuropathic pain. By directly targeting validated molecular drivers of pain, Pinco’s plasmid is designed to deliver durable, non-addictive relief while avoiding the systemic side effects of small molecules and the immunogenicity risks of viral gene therapies.